Loading company…
Stromedix develops drugs for fibrotic organ failure, including the antibody STX-100.
Founded in 2005, Stromedix is a clinical-stage biotechnology company based in Cambridge, Massachusetts. It develops drugs for fibrotic organ failure, including STX-100, a humanized monoclonal antibody with anti-fibrotic activity in preclinical models of lung, kidney and liver diseases.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in